Susquehanna International Group
ABCL icon

Susquehanna International Group’s AbCellera Biologics ABCL Stock Holding History

Susquehanna International Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.18M Buy
911,100
+525,300
+136% +$1.89M ﹤0.01% 5159
2025
Q4 		$1.32M Sell
385,800
-94,200
-20% -$420K ﹤0.01% 6549
2025
Q3 		$2.41M Buy
480,000
+170,900
+55% +$753K ﹤0.01% 5394
2025
Q2 		$1.06M Buy
309,100
+287,700
+1,344% +$716K ﹤0.01% 7262
2025
Q1 		$47.7K Sell
21,400
-13,300
-38% -$38.1K ﹤0.01% 11881
2024
Q4 		$102K Buy
34,700
+22,900
+194% +$63.8K ﹤0.01% 11334
2024
Q3 		$30.7K Sell
11,800
-51,700
-81% -$143K ﹤0.01% 11532
2024
Q2 		$188K Sell
63,500
-33,700
-35% -$128K ﹤0.01% 10455
2024
Q1 		$440K Sell
97,200
-120,100
-55% -$613K ﹤0.01% 8822
2023
Q4 		$1.24M Buy
217,300
+76,700
+55% +$355K ﹤0.01% 6457
2023
Q3 		$647K Sell
140,600
-127,700
-48% -$777K ﹤0.01% 7633
2023
Q2 		$1.73M Sell
268,300
-180,000
-40% -$1.23M ﹤0.01% 5445
2023
Q1 		$3.38M Sell
448,300
-109,700
-20% -$996K ﹤0.01% 4083
2022
Q4 		$5.65M Sell
558,000
-2,096,900
-79% -$24.2M ﹤0.01% 3054
2022
Q3 		$26.3M Buy
2,654,900
+502,000
+23% +$5.51M 0.01% 1194
2022
Q2 		$22.9M Buy
2,152,900
+2,035,400
+1,732% +$17.2M 0.01% 1343
2022
Q1 		$1.15M Buy
117,500
+51,100
+77% +$484K ﹤0.01% 6783
2021
Q4 		$950K Sell
66,400
-261,400
-80% -$3.97M ﹤0.01% 7436
2021
Q3 		$6.57M Buy
327,800
+182,100
+125% +$3.22M ﹤0.01% 3500
2021
Q2 		$3.21M Buy
+145,700
New +$4.02M ﹤0.01% 4877

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ABCL Position: Q1 2026 in Review

Susquehanna International Group reduced its AbCellera Biologics (ABCL) stake by 51% in Q1 2026, selling an estimated $2.79M and leaving 750,393 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #5561.

Susquehanna International Group first reported a position in ABCL in Q4 2020 and has held it in 21 quarters since. The position peaked at $8.71M in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Susquehanna International Group held 750,393 shares of AbCellera Biologics worth $2.62M as of Q1 2026.
  • Susquehanna International Group sold 774,170 AbCellera Biologics shares in Q1 2026, an estimated $2.79M.
  • AbCellera Biologics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5561 holding.
  • Susquehanna International Group first reported a position in AbCellera Biologics in Q4 2020 and has held it in 21 quarters since.
  • Susquehanna International Group's AbCellera Biologics position peaked at $8.71M in Q3 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.